KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Q3 2025 value amounting to -$242.4 million.

  • Jazz Pharmaceuticals' Tax Provisions fell 156809.33% to -$242.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.1 million, marking a year-over-year decrease of 39843.75%. This contributed to the annual value of -$91.4 million for FY2024, which is 2375.33% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Tax Provisions stood at -$242.4 million for Q3 2025, which was down 156809.33% from -$17.2 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Tax Provisions high stood at $228.6 million for Q2 2021, and its period low was -$242.4 million during Q3 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' median Tax Provisions value was -$17.6 million (recorded in 2021), while the average stood at -$23.0 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Tax Provisions skyrocketed by 31719.16% in 2021 and then crashed by 295895.52% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Tax Provisions (Quarter) stood at -$12.5 million in 2021, then plummeted by 701.36% to -$100.0 million in 2022, then soared by 66.92% to -$33.1 million in 2023, then plummeted by 75.02% to -$57.9 million in 2024, then tumbled by 318.61% to -$242.4 million in 2025.
  • Its last three reported values are -$242.4 million in Q3 2025, -$17.2 million for Q2 2025, and -$57.9 million during Q4 2024.